CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

Mark Wong; Rosemary L. Balleine; Michael Collins; Christopher Liddle; Christine L. Clarke; Howard Gurney

doi:10.1016/j.clpt.2004.02.005

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

Mark Wong^*, Rosemary L. Balleine, Michael Collins, Christopher Liddle, Christine L. Clarke, Howard Gurney

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

87 Citations (Scopus)

Abstract

Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population.

Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients.

Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13%) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10%) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P = .01, 2-way ANOVA).

Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.

Original language	English
Pages (from-to)	529-538
Number of pages	10
Journal	Clinical Pharmacology and Therapeutics
Volume	75
Issue number	6
DOIs	https://doi.org/10.1016/j.clpt.2004.02.005
Publication status	Published - Jun 2004
Externally published	Yes

Access to Document

10.1016/j.clpt.2004.02.005

Cite this

@article{73b746c2d4054c48bab6d6695d17dc6a,

title = "CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy",

abstract = "Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population. Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients. Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13%) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10%) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P = .01, 2-way ANOVA). Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.",

author = "Mark Wong and Balleine, {Rosemary L.} and Michael Collins and Christopher Liddle and Clarke, {Christine L.} and Howard Gurney",

year = "2004",

month = jun,

doi = "10.1016/j.clpt.2004.02.005",

language = "English",

volume = "75",

pages = "529--538",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Springer, Springer Nature",

number = "6",

}

TY - JOUR

T1 - CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

AU - Wong, Mark

AU - Balleine, Rosemary L.

AU - Collins, Michael

AU - Liddle, Christopher

AU - Clarke, Christine L.

AU - Gurney, Howard

PY - 2004/6

Y1 - 2004/6

N2 - Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population. Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients. Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13%) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10%) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P = .01, 2-way ANOVA). Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.

AB - Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population. Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients. Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13%) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10%) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P = .01, 2-way ANOVA). Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.

UR - http://www.scopus.com/inward/record.url?scp=2942560581&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2004.02.005

DO - 10.1016/j.clpt.2004.02.005

M3 - Article

C2 - 15179407

AN - SCOPUS:2942560581

SN - 0009-9236

VL - 75

SP - 529

EP - 538

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 6

ER -

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this